CY1107641T1 - Φαρμακευτικη συνθεση περιλαμβανουσα αναστολεα λιπασης και μονο-εστερα λιπαρου οξεος με σακχαροζη - Google Patents

Φαρμακευτικη συνθεση περιλαμβανουσα αναστολεα λιπασης και μονο-εστερα λιπαρου οξεος με σακχαροζη

Info

Publication number
CY1107641T1
CY1107641T1 CY20071100716T CY071100716T CY1107641T1 CY 1107641 T1 CY1107641 T1 CY 1107641T1 CY 20071100716 T CY20071100716 T CY 20071100716T CY 071100716 T CY071100716 T CY 071100716T CY 1107641 T1 CY1107641 T1 CY 1107641T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
sugaroze
fataric
inclusive
acid
Prior art date
Application number
CY20071100716T
Other languages
English (en)
Inventor
Karsten Maeder
Rainer Eugen Martin
Susanne Raab
Lukas Christoph Scheibler
Thomas Schindler
Marco Schroeder
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177654&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107641(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1107641T1 publication Critical patent/CY1107641T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

H παρούσα ευρεσιτεχνία αναφέρεται σε φαρμακευτική σύνθεση που περιλαμβάνει αναστολέα λιπάσης, κατά προτίμηση ορλιστάτη, που έχει σημείο τήξης ≥ 37°C, εστέρα λιπαρού οξέος με σακχαρόζη όπου ο εστέρας του λιπαρού οξέος με τη σακχαρόζη είναι ένας μονο-, δι-, τρι- ή τετρα-εστέρας, και προαιρετικώς ένα ή περισσότερα φαρμακευτικώς παραδεκτά έκδοχα
CY20071100716T 2001-06-06 2007-05-29 Φαρμακευτικη συνθεση περιλαμβανουσα αναστολεα λιπασης και μονο-εστερα λιπαρου οξεος με σακχαροζη CY1107641T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01113793 2001-06-06
EP02727607A EP1399152B1 (en) 2001-06-06 2002-05-29 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid mono-ester

Publications (1)

Publication Number Publication Date
CY1107641T1 true CY1107641T1 (el) 2013-04-18

Family

ID=8177654

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100716T CY1107641T1 (el) 2001-06-06 2007-05-29 Φαρμακευτικη συνθεση περιλαμβανουσα αναστολεα λιπασης και μονο-εστερα λιπαρου οξεος με σακχαροζη

Country Status (40)

Country Link
US (4) US20030027786A1 (el)
EP (1) EP1399152B1 (el)
JP (2) JP4261337B2 (el)
KR (1) KR100753729B1 (el)
CN (1) CN1514725B (el)
AR (1) AR034355A1 (el)
AT (1) ATE356622T1 (el)
AU (1) AU2002257817B2 (el)
BG (1) BG66346B1 (el)
BR (1) BRPI0210266B1 (el)
CA (1) CA2448030C (el)
CO (1) CO5540293A2 (el)
CY (1) CY1107641T1 (el)
CZ (1) CZ299948B6 (el)
DE (1) DE60218845T2 (el)
DK (1) DK1399152T3 (el)
EC (1) ECSP034871A (el)
ES (1) ES2282415T3 (el)
GT (1) GT200200106A (el)
HK (1) HK1067312A1 (el)
HR (1) HRP20030983B1 (el)
HU (1) HU230405B1 (el)
IL (2) IL158908A0 (el)
JO (1) JO2455B1 (el)
MA (1) MA27031A1 (el)
ME (1) ME00579A (el)
MX (1) MXPA03011191A (el)
MY (1) MY161871A (el)
NO (1) NO328006B1 (el)
NZ (1) NZ529630A (el)
PA (1) PA8546701A1 (el)
PE (1) PE20030230A1 (el)
PL (1) PL215266B1 (el)
PT (1) PT1399152E (el)
RS (1) RS50713B (el)
RU (1) RU2271808C2 (el)
SI (1) SI1399152T1 (el)
SK (1) SK287602B6 (el)
WO (1) WO2002098412A1 (el)
ZA (1) ZA200309007B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076A (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
PL1897558T3 (pl) * 2005-06-09 2014-01-31 Norgine Bv Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu
US20070111914A1 (en) * 2005-11-16 2007-05-17 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Environmentally friendly laundry method and kit
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR2994386B1 (fr) * 2012-08-07 2016-06-24 Thorel Jean-Noel Inhibition de l'adhesion de micro-organismes pathogenes par un ester de saccharose et/ou de sorbitan dans le traitement cosmetique de l'atopie cutanee
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
EP3364956A4 (en) 2015-10-23 2019-05-01 ERX Pharmaceuticals, Inc. CELASTROL ANALOGUES
CN113151373B (zh) * 2021-03-09 2023-07-04 武汉臻治生物科技有限公司 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用
KR102637596B1 (ko) 2022-03-18 2024-02-19 (주)보노보씨 기능성 목공교구

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965133A1 (de) 1969-12-27 1971-07-22 Merck Patent Gmbh Verfahren zur Herstellung pharmazeutischer Zubereitungen
US4148887A (en) * 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
NL8600050A (nl) 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
EP0271963B1 (en) * 1986-12-19 1993-07-21 The Procter & Gamble Company Food compositions with superior blood cholesterol lowering properties
JP2748597B2 (ja) 1989-09-28 1998-05-06 三菱化学株式会社 食品劣化抑制剤
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
JP3112473B2 (ja) 1990-10-18 2000-11-27 オリンパス光学工業株式会社 屈折率分布型光学素子の製造方法
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DK1105122T3 (da) 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
ES2217797T3 (es) 1998-08-14 2004-11-01 F. Hoffmann-La Roche Ag Vinileteres heterociclicos contra trastornos neurologicos.
WO2000025598A1 (en) 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
CA2358921A1 (en) 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
EP1296656B1 (en) * 2000-06-27 2006-08-02 F. Hoffmann-La Roche Ag Method for preparing a composition
EP1307263B1 (en) 2000-07-28 2005-04-20 F. Hoffmann-La Roche Ag New use of lipase inhibitors
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6534097B1 (en) * 2002-07-11 2003-03-18 Betty Baggott Pest repellent

Also Published As

Publication number Publication date
WO2002098412A1 (en) 2002-12-12
HRP20030983A2 (en) 2005-08-31
MA27031A1 (fr) 2004-12-20
ZA200309007B (en) 2005-04-26
CA2448030C (en) 2009-11-24
DE60218845D1 (de) 2007-04-26
HK1067312A1 (en) 2005-04-08
BRPI0210266B1 (pt) 2016-01-26
CN1514725B (zh) 2010-04-21
KR20040010689A (ko) 2004-01-31
PT1399152E (pt) 2007-06-05
IL158908A0 (en) 2004-05-12
US20110301231A1 (en) 2011-12-08
MY161871A (en) 2017-05-15
US8039508B2 (en) 2011-10-18
US20030027786A1 (en) 2003-02-06
AR034355A1 (es) 2004-02-18
BR0210266A (pt) 2004-07-20
HUP0401208A3 (en) 2008-04-28
KR100753729B1 (ko) 2007-08-30
ECSP034871A (es) 2004-01-28
RU2003136728A (ru) 2005-05-20
CZ20033525A3 (cs) 2004-04-14
ATE356622T1 (de) 2007-04-15
US20130079391A1 (en) 2013-03-28
BG66346B1 (bg) 2013-08-30
HRP20030983B1 (en) 2011-10-31
SK16092003A3 (sk) 2004-05-04
CO5540293A2 (es) 2005-07-29
ES2282415T3 (es) 2007-10-16
GT200200106A (es) 2003-02-11
JP2004532271A (ja) 2004-10-21
PA8546701A1 (es) 2003-01-24
CA2448030A1 (en) 2002-12-12
HUP0401208A2 (hu) 2004-11-29
RU2271808C2 (ru) 2006-03-20
US20050101562A1 (en) 2005-05-12
IL158908A (en) 2008-08-07
NO328006B1 (no) 2009-11-09
SI1399152T1 (sl) 2007-08-31
US8343543B2 (en) 2013-01-01
BG108421A (en) 2005-02-28
JO2455B1 (en) 2008-10-09
CN1514725A (zh) 2004-07-21
EP1399152B1 (en) 2007-03-14
DK1399152T3 (da) 2007-06-18
NZ529630A (en) 2006-05-26
MXPA03011191A (es) 2004-02-26
JP2009108076A (ja) 2009-05-21
PL215266B1 (pl) 2013-11-29
HU230405B1 (hu) 2016-04-28
ME00579B (me) 2011-12-20
JP4261337B2 (ja) 2009-04-30
AU2002257817B2 (en) 2005-08-18
CZ299948B6 (cs) 2009-01-07
PE20030230A1 (es) 2003-03-17
RS50713B (sr) 2010-06-30
NO20035318D0 (no) 2003-11-28
PL366890A1 (en) 2005-02-07
DE60218845T2 (de) 2008-01-03
ME00579A (en) 2011-12-20
RS96003A (en) 2006-10-27
EP1399152A1 (en) 2004-03-24
SK287602B6 (sk) 2011-03-04

Similar Documents

Publication Publication Date Title
CY1107641T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα αναστολεα λιπασης και μονο-εστερα λιπαρου οξεος με σακχαροζη
DOP2001000224A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.
EE200400024A (et) Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
BR0112584A (pt) ésteres oxigenados de ácidos benzidroxâmicos de 4-iodofenilamino
IS7714A (is) Lyfjasamsetningar úr módafíníl
CY1105586T1 (el) Ιμιδαζοκουινολινες υποκατεστημενες με θειοαιθερα
ID29158A (id) Monoester probukol untuk pengobatan penyakit kardiovaskular dan peradangan
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
BR9606520A (pt) Método para detectar a ampliação de uma sequência alvo
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
DE60233436D1 (de) In der mundhöhle dispergierbare feste pharmazeutische form
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
CY1106201T1 (el) Αναλογα δισκοδepμολιδης και η φαρμακευτικη τους χρηση
NO20044903L (no) Anvendelse av nye etonogestrel estere
ITMI20001985A0 (it) Varianti dell'allergene maggiore par j 2 di parietaria judaica
ES2324040T3 (es) Copolimeros de 1-vinilpirrolidin-2-ona ester.
UY27321A1 (es) Nueva composición farmacéutica
ATE133647T1 (de) 3-aryl- und 3-heteroaryl-2-fluor-1-olefine mit pharmazeutischer wirkung
FI20001079A (fi) Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen uudet prodrugit, niiden valmistus ja käyttö
IDP000026456A (id) Senyawa-senyawa siklopropanakarboksilat ester
ITMI20021455A0 (it) Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
MC200002A1 (fr) Nouveaux agents immunomodulateurs emulsions de fluorocarbures stabilisées par des carbamates polyfluorés